<DOC>
	<DOCNO>NCT00000973</DOCNO>
	<brief_summary>To determine manner pyrimethamine metabolize excreted patient currently receive zidovudine ( AZT ) . An important goal measurement establish optimal dose pyrimethamine necessary prevent development toxoplasmosis AIDS patient delay subsequent return toxoplasmic encephalitis . Encephalitis cause Toxoplasma gondii emerge frequent cause focal central nervous system infection patient AIDS . Untreated , encephalitis fatal . The best treatment disease determine . Presently standard practice administer combination pyrimethamine sulfadiazine . Little known pharmacokinetics pyrimethamine patient AIDS receive AZT . Furthermore , report patient already expose toxoplasmosis may uniform absorption pyrimethamine .</brief_summary>
	<brief_title>A Study Pyrimethamine Treatment Infection Certain Parasite HIV-Positive Patients</brief_title>
	<detailed_description>Encephalitis cause Toxoplasma gondii emerge frequent cause focal central nervous system infection patient AIDS . Untreated , encephalitis fatal . The best treatment disease determine . Presently standard practice administer combination pyrimethamine sulfadiazine . Little known pharmacokinetics pyrimethamine patient AIDS receive AZT . Furthermore , report patient already expose toxoplasmosis may uniform absorption pyrimethamine . Patients receive study treatment total 22 day . Patients give initial dose pyrimethamine follow low dose give single oral daily dose 21 day . Patients continue receive AZT dose prescribe prior enrollment study . Patients receive leucovorin calcium day . Neither leucovorin calcium AZT provide study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Toxoplasmosis</mesh_term>
	<mesh_term>Toxoplasmosis , Cerebral</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized pentamidine Pneumocystis carinii pneumonia prophylaxis . Isoniazid initiate study period . Methadone maintenance . Required : Stable prescribed dose zidovudine ( AZT ) least 500 mg/day . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Prior history toxoplasmic encephalitis . Unable take oral medication reliably malabsorption syndrome ( i.e. , 3 loose stools/day least 4 week associate unintentional weight loss = &gt; 10 percent body weight ) . History sensitivity study medication . Concurrent Medication : Excluded : Maintenance therapy opportunistic infection macrolides sulfonamide , immunomodulators , rifampin , amphotericin , dapsone , ganciclovir , antifolates , probenecid , benzodiazepine , nephrotoxin , experimental cytotoxic chemotherapy . Medications aspirin , benzodiazepine , cimetidine , indomethacin , morphine , sulfonamide avoid . Concurrent Treatment : Excluded : Lymphocyte replacement . Patients follow excluded : Any medical social condition , opinion investigator , would adversely affect either participation compliance study . Diagnosis AIDS febrile evidence another serious opportunistic infection central nervous system impairment . Prior Medication : Excluded : Maintenance therapy opportunistic infection macrolides sulfonamide , immunomodulators , rifampin , amphotericin , dapsone , ganciclovir , antifolates , probenecid , benzodiazepine , nephrotoxin , experimental cytotoxic chemotherapy within past 14 day . Prior Treatment : Excluded : Lymphocyte replacement within past 14 day . Patients follow symptoms condition : Laboratory evidence HIV infection . Serological evidence exposure Toxoplasma gondii , clinical evidence active toxoplasmic infection . Able understand sign write informed consent . Either homosexual male intravenous drug user . Required : Stable prescribed dose zidovudine ( AZT ) least 500 mg/day 4 week . Intravenous drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Toxoplasmosis</keyword>
	<keyword>Toxoplasma</keyword>
	<keyword>Pyrimethamine</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Encephalitis</keyword>
	<keyword>Zidovudine</keyword>
</DOC>